MolGraph
CompoundsDocumentationComplianceAbout
MolGraph

Research chemical sourcing and molecular building block RFQ workflows.

MolGraph is operated by Tessorix Inc.

support@molgraph.com

Products are intended for laboratory research use only and are not for human or veterinary use.

Compounds

  • Compound catalog
  • CAS Search

Company

  • About
  • Contact

Documentation

  • Quality Documentation
  • SDS Disclaimer

Compliance

  • Compliance

Legal

  • Terms
  • Privacy

Copyright © 2026 MolGraph. All Rights Reserved.

Home/Compounds/CAS 389-08-2
Formula C12H12N2O3MW 232.23Research-use catalog entryCOA/SDS by request

Nalidixic Acid

CAS Number: 389-08-2

Sourcing & RFQ

Submit an RFQ to review pricing, availability, lead time, pack size, purity, COA, and supplier SDS for this catalog entry.

Available options

Available Options

Package
100 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
25 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
5 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required

Shipping review is required before pricing or stock can be confirmed publicly. Shipping, duties, and documentation fees are confirmed before order acceptance.

Loading RDKit molecule structure...
InChIKey: MHWLWQUZZRMNGJ-UHFFFAOYSA-NC12H12N2O3 | MW 232.23

Chemical Absolute Identifiers

CAS Number

389-08-2

PubChem CID

4421

Molecular Formula

C12H12N2O3

Molecular Weight

232.23 g/mol

Exact Mass

232.084792

InChIKey

MHWLWQUZZRMNGJ-UHFFFAOYSA-N

IUPAC Name

1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid

SMILES String

CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O

Physical Properties

Appearance

Nalidixic acid is a cream-colored powder. (NTP, 1992)

Melting Point

228.89–23 °C

Properties are provided as catalog reference data and may be confirmed through supplier documentation when required.

Catalog Facts

Structural features

Nalidixic Acid (CAS 389-08-2) is listed in the Pharmaceutical Intermediates portfolio, with molecular formula C12H12N2O3 and molecular weight 232. 23 g/mol.

Sourcing context

Catalog reference for RFQ preparation, supplier confirmation, and research chemical sourcing review.

Research use context

Intended for research-stage medicinal chemistry and intermediate synthesis workflows; structure-derived tags include nitrogen-containing heterocycle.

Documentation needs

COA/SDS status, availability, lead time, pack size, and shipment documentation can be confirmed during quotation.

Applications & Classification

Pharmaceutical Intermediate ResearchResearch intermediateCustom synthesis building blockPharmaceutical intermediate researchResearch chemical sourcingCustom synthesis and catalog availability reviewCOA, SDS, pricing, and fulfillment workflow
Biological target reference

ChEMBL reports experimental activity evidence for: Prostaglandin G/H synthase 1 (Homo sapiens) — 3 assays; Pyruvate kinase PKM (Homo sapiens) — 3 assays; DNA gyrase (Escherichia coli) — 8 assays; DNA topoisomerase 2-beta (Homo sapiens) — 8 assays; Transthyretin (Homo sapiens) — 4 assays. These records describe research assays and do not establish therapeutic efficacy or clinical use.

Prostaglandin G/H synthase 1

Homo sapiens · SINGLE PROTEIN · 3 qualifying assays · 2 documents · best pChEMBL 5.14

Experimental evidence source: ChEMBL

Pyruvate kinase PKM

Homo sapiens · SINGLE PROTEIN · 3 qualifying assays · 3 documents · best pChEMBL 4.28

Experimental evidence source: ChEMBL

DNA gyrase

Escherichia coli · PROTEIN COMPLEX · 8 qualifying assays · 6 documents · best pChEMBL 4

Experimental evidence source: ChEMBL

DNA topoisomerase 2-beta

Homo sapiens · SINGLE PROTEIN · 8 qualifying assays · 3 documents

Experimental evidence source: ChEMBL

Transthyretin

Homo sapiens · SINGLE PROTEIN · 4 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Safety & Handling

Handling & Storage

  • Keep container tightly closed and dry.
  • Store in a well-ventilated place.

PPE

Respiratory protection if needed

First Aid

  • Do not give anything to an unconscious person.
  • Rinse mouth with water.

Stability / Reactivity

  • Reactivity.
  • Carbon monoxide, carbon dioxide, nitrogen oxides.

Disposal

  • Waste product.
  • Dispose of remaining and non-recyclable solutions to a licensed company.
Show additional safety reference fields

Fire Fighting

  • If necessary, wear a self-contained breathing apparatus for firefighting.

Accidental Release

  • Do not generate dust when collecting and disposing.
  • Sweep and shovel up.

For supplier-issued SDS, request documentation before handling, storage, shipment, or procurement decisions.

Preliminary Safety Reference

For supplier-issued SDS or COA, submit a documentation request.

Safety Reference / SDS Request

Names & Synonyms / External Identifiers

Chemical Name

Nalidixic Acid

Names & Synonyms

NalidixinNegGramNevigramonNalidixanNalidic acid
Show all synonyms
Nalidixinic acidWintomylonDixibenNalurinNaxurilNogramUrisalNalix1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acidBetaxinaSpecifinUrodixinNegramUralginUriben
External Identifiers
EC NUMBER: 206-864-7DSSTOX SUBSTANCE ID: DTXSID3020912CHEMBL ID: CHEMBL5CHEBI ID: CHEBI:100147UNII: 3B91HWA56MDRUGBANK ID: DB00779HMDB ID: HMDB0014917KEGG ID: C05079KEGG ID: D00183METABOLOMICS WORKBENCH ID: 43074NCI THESAURUS CODE: C47630PHARMGKB ID: PA164746384WIKIDATA ID: Q281082
Experimental Spectrum References
13C NMR Spectra1D NMR Spectra1H NMR SpectraATR-IR Spectra — Bio-Rad Laboratories, Inc.FTIR SpectraRaman SpectraUV-VIS SpectraVapor Phase IR Spectra
Literature & Patent References
DOI 10.1016/j.isci.2024.108907Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelDOI 10.1021/acs.jmedchem.3c01512Mechanistic Investigation of Thiazole-Based Pyruvate Kinase M2 Inhibitor Causing Tumor Regression in Triple-Negative Breast Cancer.PMID 38318365Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelPMID 38408027Mechanistic Investigation of Thiazole-Based Pyruvate Kinase M2 Inhibitor Causing Tumor Regression in Triple-Negative Breast Cancer.DOI 10.1016/j.bmc.2023.117203Ionization and lipophilicity in nonpolar media mimicking the cell membrane interior.DOI 10.1038/s41467-023-40064-9A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.PMID 36796127Ionization and lipophilicity in nonpolar media mimicking the cell membrane interior.PMID 37468498A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Documentation & Compliance Facts

Compliance Facts

Shipment review: Required

Documentation available by request

Certificate of Analysis (COA): By request

Supplier Safety Data Sheet (SDS): By request

Purity and pack size confirmation: By request

Availability and lead time review: Confirmed by RFQ

Shipment documentation review: By request

For supplier-issued documentation by request, use the RFQ actions on this page.Review preliminary safety reference

What happens after RFQ

  1. 1We review the CAS identity, quantity, and documentation request.
  2. 2We check sourcing options, supplier availability, COA/SDS, purity, pack size, and lead time.
  3. 3We review destination and shipment documentation needs when applicable.
  4. 4We follow up with a quotation or clarification request.

Text Reference Cues

Show non-linked catalog cues

Non-public related references

Piromidic AcidCAS 19562-30-2
1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrate (2:3)CAS 84294-96-2
PefloxacinCAS 70458-92-3
NorfloxacinCAS 70458-96-7
FleroxacinCAS 79660-72-3

Non-public references are shown as text only and do not imply equivalence, availability, or shared use.

Catalog navigation

Related Catalog Entries

Other public CAS pages in this catalog. These links support navigation across additional intermediates and do not imply equivalence, availability, or shared use.

CAS 19562-30-2Piromidic AcidCAS 84294-96-21,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrate (2:3)CAS 97-18-7BithionolCAS 21829-25-4NifedipineCAS 111974-69-7QuetiapineCAS 525-79-1KinetinCAS 520-36-5ApigeninCAS 1002310-00-0Tert-butyl 1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylcarbamateCAS 1005174-17-3(E)-3-(2-Propyl-6-(trifluoromethyl)pyridin-3-yl)acrylic acidCAS 1018125-49-92-(3-Cyclopropyl-6-ethyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetic acid

RFQ questions for CAS 389-08-2

What are the key identifiers for Nalidixic Acid (CAS 389-08-2)?

Nalidixic Acid is identified by CAS 389-08-2, with molecular formula C12H12N2O3, molecular weight 232.23, InChIKey MHWLWQUZZRMNGJ-UHFFFAOYSA-N.

Does CAS 389-08-2 have reported biological target evidence?

ChEMBL contains qualifying experimental assay evidence associated with Prostaglandin G/H synthase 1, Pyruvate kinase PKM, DNA gyrase, DNA topoisomerase 2-beta, Transthyretin. These records do not establish therapeutic efficacy or clinical use.

Can I request a COA for CAS 389-08-2?

Yes. Submit an RFQ and specify COA requirements. Lot-specific COA depends on supplier confirmation.

Can I request supplier SDS for Nalidixic Acid?

Yes. Supplier SDS can be requested through the RFQ workflow before handling, storage, shipment, or procurement decisions.

Is CAS 389-08-2 available for quotation?

Availability, pack size, lead time, and pricing are confirmed through RFQ.

Can MolGraph support bulk sourcing or custom synthesis review?

Submit the CAS number, quantity, purity requirement, and destination country for sourcing review.